Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1446491

Xytis Inc. - Product Pipeline Review - Q4 2010

Description:
Xytis Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Xytis Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Xytis Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Xytis Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Xytis Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Xytis Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Xytis Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Xytis Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Xytis Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Xytis Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Xytis Inc. and identify potential opportunities in those areas.
 
Contents:

List of Tables
List of Figures
Xytis Inc. Snapshot
Xytis Inc. Overview
Key Information
Key Facts
Xytis Inc. – Research and Development Overview
Key Therapeutic Areas
Xytis Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Xytis Inc. – Pipeline Products Glance
Xytis Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Xytis Inc.–Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Xytis Inc. – Drug Profiles
XY2405
Product Description
Mechanism of Action
R&D Progress
XY2401
Product Description
Mechanism of Action
R&D Progress
XY2411
Product Description
Mechanism of Action
R&D Progress
Xytis Inc. – Pipeline Analysis
Xytis Inc. – Pipeline Products by Therapeutic Class
Xytis Inc. Pipeline Products By Target
Xytis Inc. – Pipeline Products by Route of Administration
Xytis Inc. – Pipeline Products by Molecule Type
Xytis Inc. – Recent Pipeline Updates
Xytis Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
XY1029
XY2412
XY4083
Xytis Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 18, 2008: Xytis Announces To Initiate First In Class Phase I Clinical Trials With XY4083
Nov 18, 2008: Xytis Announces To Initiate First In Class Phase I Clinical Trials With XY4083
Mar 13, 2007: Xytis Enrolls First Patient In Phase II Clinical Study With Anatibant (XY2405) For Traumatic Brain Injury
Nov 16, 2005: Xytis Pharmaceuticals Commences Phase I Clinical Trial Of XY 2401 In Schizophrenia
Jun 13, 2005: Fournier Pharma And Xytis Pharmaceuticals Sign Licence Agreement For XY 2405
Jan 11, 2005: Rottapharm And Xytis Parmaceuticals Enter Into Global Licensing Agreement For XY 2401
Jan 11, 2005: Rottapharm And Xytis Parmaceuticals Enter Into Global Licensing Agreement For XY 2401
Financial Deals Landscape
Xytis Inc., Deals Summary, 2004 to 2010
Xytis Inc. Detailed Deal Summary
Venture Financing
Xytis Secures $15 Million In Series B Funding
Licensing Agreements
Fournier Pharma Enters Into Licensing Agreement With Xytis Pharmaceuticals
Rottapharm Enters Into Licensing Agreement With Xytis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1446491

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Jul 31th 2014
3:31:44 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Xytis Inc. - Product Pipeline Review - Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1446491

Office Code

OC8DIMOSRRTVTZ

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Jul 31th 2014
3:31:44 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)